DSTN低甲基化通过激活Wnt/β-catenin信号通路促进直肠癌放疗抵抗
研究按术后肿瘤消退分级选取直肠癌患者,比较放疗抵抗与敏感组织中差异基因,发现DSTN在放疗抵抗组织中高表达且低甲基化,高表达者无病生存期更短;体外和体内实验显示敲低DSTN促进放疗敏感性、过表达促进放疗抵抗,机制涉及DSTN结合β-catenin并增加其稳定性。
要点
- DSTN在直肠癌放疗抵抗组织中高表达(P < .05)且低甲基化(P < .01)。
- 放疗抵抗组织中DSTN高表达患者无病生存期更短(P < .05)。
- 敲低DSTN促进结直肠癌细胞放疗敏感性,过表达促进放疗抵抗(P < .05)。
核心结论
- DNA甲基化程度和DSTN表达水平可作为预测直肠癌新辅助放疗敏感性的生物标志物。
- DSTN和β-catenin有望成为新辅助放疗选择的参考。
研究设计与样本
- 根据术后肿瘤消退分级选取直肠癌患者,取肿瘤样本进行检测。
- 采用Illumina Infinium MethylationEPIC BeadChip、蛋白质组学、Agena MassARRAY甲基化检测、逆转录定量实时聚合酶链反应和免疫组化筛选并验证放疗抵抗与敏感组织间的差异基因。
- 通过体外和体内功能实验验证DSTN的作用。
- 采用蛋白质免疫共沉淀、蛋白质印迹和免疫荧光研究DSTN相关放疗抵抗的机制。
主要发现
- DSTN在新辅助放疗抵抗的直肠癌组织中高表达(P < .05)且低甲基化(P < .01)。
- 随访数据证实新辅助放疗抵抗的直肠癌组织中DSTN高表达患者无病生存期更短(P < .05)。
- 在结直肠癌细胞中,甲基转移酶抑制剂抑制DNA甲基化后DSTN表达增加(P < .05)。
- 体外和体内实验显示敲低DSTN促进结直肠癌细胞对放疗的敏感性,过表达DSTN促进结直肠癌细胞对放疗的抵抗(P < .05)。
- 过表达DSTN的结直肠癌细胞中Wnt/β-catenin信号通路被激活;放疗抵抗组织中β-catenin高表达,DSTN与β-catenin表达呈线性相关(P < .0001);DSTN可结合β-catenin并增加其稳定性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although surgical resection combined with neoadjuvant radiation therapy can reduce the local recurrence rate of rectal cancer, not all patients benefit from neoadjuvant radiation therapy. Therefore, screening for patients with rectal cancer who are sensitive or resistant to radiation therapy has great clinical significance. METHODS AND MATERIALS: Patients with rectal cancer were selected according to postoperative tumor regression grade, and tumor samples were taken for detection. Differential genes between radiation-resistant and radiation-sensitive tissues were screened and validated by Illumina Infinium MethylationEPIC BeadChip, proteomics, Agena MassARRAY methylation, reverse transcription quantitative real-time polymerase chain reaction, and immunohistochemistry. In vitro and in vivo functional experiments verified the role of DSTN. Protein coimmunoprecipitation, western blot, and immunofluorescence were used to investigate the mechanisms of DSTN-related radiation resistance. RESULTS: DSTN was found to be highly expressed (P < .05) and hypomethylated (P < .01) in rectal cancer tissues resistant to neoadjuvant radiation therapy. Follow-up data confirmed that patients with high expression of DSTN in neoadjuvant radiation therapy-resistant rectal cancer tissues had shorter disease-free survival (P < .05). DSTN expression increased after methyltransferase inhibitor inhibition of DNA methylation in colorectal cancer cells (P < .05). In vitro and in vivo experiments showed that knockdown of DSTN promoted the sensitivity of colorectal cancer cells to radiation therapy, and overexpression of DSTN promoted the resistance of colorectal cancer cells to radiation (P < .05). The Wnt/β-catenin signaling pathway was activated in colorectal cancer cells overexpressing DSTN. β-catenin was highly expressed in radiation therapy-resistant tissues, and there was a linear correlation between the expression of DSTN and β-catenin (P < .0001). Further studies showed that DSTN can bind to β-catenin and increase its stability. CONCLUSIONS: The degree of DNA methylation and the expression level of DSTN can be used as biomarkers to predict the sensitivity of neoadjuvant radiation therapy for rectal cancer. DSTN and β-catenin are also expected to become a reference for the selection of neoadjuvant radiation therapy.
引用
- Wen R, Zhou L, Jiang S, et al. DSTN Hypomethylation Promotes Radiotherapy Resistance of Rectal Cancer by Activating the Wnt/β-Catenin Signaling Pathway. Int J Radiat Oncol Biol Phys. 2023. PMID: 37019366. doi:10.1016/j.ijrobp.2023.03.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。